Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan ...

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP ...

Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment ...

One of the newest drugs for migraine, AXS-07 (Symbravo) received FDA approval on Jan. 31, 2025. AXS-07 is approved to treat acute migraine attacks. Here’s how it was made, why it’s safe ...

US CNS-focused biopharma firm Axsome Therapeutics today announced that the EMERGE Phase III trial of Symbravo (MoSEIC ...

FDA Approves Symbravo for Acute Treatment of Migraine in Adults By Lori Solomon HealthDay Reporter WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

Symbravo received FDA approval on January 30, 2025, for acute migraine treatment, and preparations for its launch are underway. CFO Nick Pizzie reported total revenues of $118.8 million for Q4 ...

Knepper was not involved in the development of or clinical trials for AXS-07 (Symbravo). Laurie Knepper, MD Migraine is a disabling neurological disease that can cause throbbing head pain ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

47.9% of patients reported sustained pain relief for 24 hours with Symbravo, compared to 16.7% with oral CGRP inhibitors. In the trial, Symbravo rapidly and substantially improved migraine pain ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. The approval was ...